GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Mutant KRas is a significant driver of human oncogenesis and confers resistance to therapy, underscoring the need to develop approaches that disable mutant KRas-driven tumors. Because targeting KRas directly has proven difficult, identifying vulnerabilities specific for mutant KRas tumors is an impo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazi, Aslamuzzaman, Xiang, Shengyan, Yang, Hua, Delitto, Daniel, Trevino, José, Jiang, Rays H. Y., Ayaz, Muhammad, Lawrence, Harshani R., Kennedy, Perry, Sebti, Saïd M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279809/
https://www.ncbi.nlm.nih.gov/pubmed/30514931
http://dx.doi.org/10.1038/s41467-018-07644-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279809/
https://www.ncbi.nlm.nih.gov/pubmed/30514931
http://dx.doi.org/10.1038/s41467-018-07644-6

Ejemplares similares